40
Participants
Start Date
March 29, 2019
Primary Completion Date
May 20, 2020
Study Completion Date
November 30, 2021
Sintilimab
"To evaluate the short-term objective efficacy of sintilimab combined with chidamide in the treatment of refractory and relapsed ENKTCL patients, and to determine the MTD, DLT/RP2D of chidamide.~To evaluate the long-term efficacy and safety of sintilimab combined with chidmide in the treatment of refractory and relapsed ENKTCL patients. Exploring biomarkers that may have predictive effects."
Chidamide
"To evaluate the short-term objective efficacy of sintilimab combined with chidamide in the treatment of refractory and relapsed ENKTCL patients, and to determine the MTD, DLT/RP2D of chidamide.~To evaluate the long-term efficacy and safety of sintilimab combined with chidmide in the treatment of refractory and relapsed ENKTCL patients. Exploring biomarkers that may have predictive effects."
Department of hematology department, Nanfang hospital, Guangzhou
Guangdong General Hospital; Guangdong Provincial People's Hospital, Guangzhou
Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan
Sun Yat-sen University Cancer Center, Guangzhou
Huiqiang Huang
OTHER